이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Zynex 관리

관리 기준 확인 4/4

Zynex's CEO는 Thomas Sandgaard, Jan1996 에 임명되었습니다 의 임기는 28.42 년입니다. 총 연간 보상은 $ 1.22M, 53.4% 로 구성됩니다. 53.4% 급여 및 46.6% 보너스(회사 주식 및 옵션 포함). 는 $ 146.60M 가치에 해당하는 회사 주식의 50.48% 직접 소유합니다. 146.60M. 경영진과 이사회의 평균 재임 기간은 각각 3.6 년과 6.4 년입니다.

주요 정보

Thomas Sandgaard

최고 경영자

US$1.2m

총 보상

CEO 급여 비율	53.4%
CEO 임기	28.4yrs
CEO 소유권	50.5%
경영진 평균 재임 기간	3.6yrs
이사회 평균 재임 기간	6.4yrs

최근 관리 업데이트

Recent updates

Earnings Update: Here's Why Analysts Just Lifted Their Zynex, Inc. (NASDAQ:ZYXI) Price Target To US$19.88

May 03

Earnings Miss: Zynex, Inc. Missed EPS By 33% And Analysts Are Revising Their Forecasts

Mar 03

Zynex begins enrollment in blood loss detection trial for CM-1600 monitoring system

Sep 21

These 4 Measures Indicate That Zynex (NASDAQ:ZYXI) Is Using Debt Safely

Aug 02

Zynex Cures The Pain Of Its Shareholders: Q2 Results

Aug 01

Zynex: Upside Looks Well Priced In, Efficiency Headwinds Remain

Jul 25

Is Zynex, Inc. (NASDAQ:ZYXI) Trading At A 46% Discount?

Jul 12

Zynex June and Q2 orders hit all-time high, re-affirms Q2 and FY22 guidance

Jul 11

Is It Time To Consider Buying Zynex, Inc. (NASDAQ:ZYXI)?

Apr 13

Zynex (NASDAQ:ZYXI) Seems To Use Debt Quite Sensibly

Mar 23

Zynex: Letter Indicates UnitedHealthcare Is Terminating Contract - An Undisclosed Loss Accounting For 50%+ EBITDA

Feb 17

CEO 보상 분석

Thomas Sandgaard 의 보수는 Zynex 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Mar 31 2024	n/a	n/a	US$8m
Dec 31 2023	US$1m	US$650k	US$10m
Sep 30 2023	n/a	n/a	US$16m
Jun 30 2023	n/a	n/a	US$17m
Mar 31 2023	n/a	n/a	US$17m
Dec 31 2022	US$1m	US$575k	US$17m
Sep 30 2022	n/a	n/a	US$18m
Jun 30 2022	n/a	n/a	US$20m
Mar 31 2022	n/a	n/a	US$19m
Dec 31 2021	US$988k	US$496k	US$17m
Sep 30 2021	n/a	n/a	US$10m
Jun 30 2021	n/a	n/a	US$5m
Mar 31 2021	n/a	n/a	US$5m
Dec 31 2020	US$1m	US$480k	US$9m
Sep 30 2020	n/a	n/a	US$10m
Jun 30 2020	n/a	n/a	US$11m
Mar 31 2020	n/a	n/a	US$10m
Dec 31 2019	US$527k	US$480k	US$9m
Sep 30 2019	n/a	n/a	US$9m
Jun 30 2019	n/a	n/a	US$10m
Mar 31 2019	n/a	n/a	US$10m
Dec 31 2018	US$1m	US$480k	US$10m
Sep 30 2018	n/a	n/a	US$10m
Jun 30 2018	n/a	n/a	US$10m
Mar 31 2018	n/a	n/a	US$9m
Dec 31 2017	US$808k	US$398k	US$7m

보상 대 시장: Thomas 의 총 보상 ($USD 1.22M )은 US 시장에서 비슷한 규모의 회사의 평균 수준입니다( $USD 1.62M ).

보상과 수익: Thomas 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Thomas Sandgaard (65 yo)

28.4yrs

테뉴어

US$1,217,895

보상

Mr. Thomas Sandgaard founded Zynex, Inc. in 1996 and has been its Chairman, Chief Executive Officer and President since 1996. Mr. Sandgaard served as the Chief Financial Officer and Chief Accounting Office...

리더십 팀

이름	위치	테뉴어	보상	소유권
Thomas Sandgaard	Founder	28.4yrs	US$1.22m	50.48% $ 149.5m
Daniel Moorhead	Chief Financial Officer	7yrs	US$883.15k	0.18% $ 537.5k
Anna Lucsok	Chief Operating Officer	3.4yrs	US$714.40k	0.24% $ 696.9k
Steve Fox	Vice President Of Sales	no data	데이터 없음	데이터 없음
Donald Gregg	President of Zynex Monitoring Solutions	1.4yrs	데이터 없음	데이터 없음
Neil Friery	President & COO of Zynex Monitoring Solutions	3.6yrs	데이터 없음	데이터 없음

3.6yrs

평균 재임 기간

52yo

평균 연령

경험이 풍부한 관리: ZYXI 의 관리팀은 경험 ( 3.6 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Thomas Sandgaard	Founder	28.4yrs	US$1.22m	50.48% $ 149.5m
Barry Michaels	Independent Director	6.4yrs	US$159.70k	0.20% $ 581.7k
Michael Cress	Independent Director	6.4yrs	US$154.70k	0.20% $ 581.7k
Joshua Disbrow	Independent Director	6.3yrs	US$154.70k	0.20% $ 581.7k

6.4yrs

평균 재임 기간

65.5yo

평균 연령

경험이 풍부한 이사회: ZYXI 의 이사회는 경험(평균 재직 기간 6.4 년)으로 간주됩니다.

Zynex 관리

관리 기준 확인 4/4

주요 정보

최근 관리 업데이트

Zynex, Inc., Annual General Meeting, May 16, 2024

Chief Financial Officer recently sold US$170k worth of stock

Chief Financial Officer notifies of intention to sell stock

Insufficient new directors

Chief Financial Officer recently sold US$407k worth of stock

Insufficient new directors

Recent updates

Earnings Update: Here's Why Analysts Just Lifted Their Zynex, Inc. (NASDAQ:ZYXI) Price Target To US$19.88

Zynex, Inc. Provides Earnings Guidance for the Second Quarter of 2024 and Reaffirms for the Full Year 2024

Price target increased by 8.1% to US$19.88

First quarter 2024 earnings released: EPS: US$0 (vs US$0.043 in 1Q 2023)

Zynex, Inc. to Report Q1, 2024 Results on Apr 30, 2024

Zynex, Inc., Annual General Meeting, May 16, 2024

Consensus EPS estimates fall by 11%

Earnings Miss: Zynex, Inc. Missed EPS By 33% And Analysts Are Revising Their Forecasts

Full year 2023 earnings: EPS and revenues miss analyst expectations

Zynex, Inc. Provides Earnings Guidance First Quarter and Full Year 2024

Zynex, Inc. to Report Q4, 2023 Results on Feb 29, 2024

Zynex, Inc. Introduces New Products

Zynex, Inc. Receives FDA Clearance for its Next Generation NMES Device

Why Investors Shouldn't Be Surprised By Zynex, Inc.'s (NASDAQ:ZYXI) P/E

Zynex, Inc. Submits FDA Application for Its NMES Device

Zynex, Inc. (NasdaqGS:ZYXI) announces an Equity Buyback for $20 million worth of its shares.

Zynex, Inc. Provides Earnings Guidance for Fourth Quarter and Full Year of 2023

Third quarter 2023 earnings: EPS exceeds analyst expectations

Price target decreased by 24% to US$16.50

Investor sentiment deteriorates as stock falls 15%

Zynex, Inc. to Report Q3, 2023 Results on Oct 26, 2023

Now 23% undervalued after recent price drop

Now 22% undervalued after recent price drop

Investor sentiment improves as stock rises 16%

Zynex, Inc. (NasdaqGS:ZYXI) announces an Equity Buyback for $10 million worth of its shares.

Now 23% undervalued after recent price drop

Chief Financial Officer recently sold US$170k worth of stock

Chief Financial Officer notifies of intention to sell stock

Investor sentiment deteriorates as stock falls 16%

Is Zynex (NASDAQ:ZYXI) Using Too Much Debt?

Second quarter 2023 earnings: EPS exceeds analyst expectations

Price target increased by 11% to US$24.00

Zynex, Inc. to Report Q2, 2023 Results on Jul 27, 2023

Zynex, Inc. Confirms Earnings Guidance for the Second Quarter of 2023 and Reiterates Earnings Guidance for the Full Year 2023

Zynex, Inc. (NasdaqGS:ZYXI) announces an Equity Buyback for $10 million worth of its shares.

Investor sentiment improves as stock rises 30%

Are Investors Undervaluing Zynex, Inc. (NASDAQ:ZYXI) By 43%?

Full year 2022 earnings: EPS exceeds analyst expectations

Investor sentiment deteriorates as stock falls 24%

Should You Be Adding Zynex (NASDAQ:ZYXI) To Your Watchlist Today?

Zynex, Inc. Reaffirms Earnings Guidance for the Fourth Quarter and Full Year 2022

Now 25% undervalued

Insufficient new directors

Chief Financial Officer recently sold US$407k worth of stock

Investor sentiment improved over the past week

Zynex, Inc. (NasdaqGS:ZYXI) announces an Equity Buyback for $10 million worth of its shares.

Third quarter 2022 earnings: EPS exceeds analyst expectations

Zynex, Inc. Provides Revenue Guidance for the Fourth Quarter 2022

Zynex, Inc. to Report Q3, 2022 Results on Oct 27, 2022

Zynex, Inc. Re-Iterates Earnings Guidance for the Full Year 2022

Short Squeeze Candidate With Low PEG Ratio: Zynex

Zynex, Inc. Begins Enrollments in Large-Scale Blood Loss Detection Clinical Trial with its Second-Generation Monitoring System, CM-1600

Zynex begins enrollment in blood loss detection trial for CM-1600 monitoring system

Zynex, Inc. Announces First Enrollments in Apheresis Donation Clinical Trial with Second Generation Fluid Monitoring System

These 4 Measures Indicate That Zynex (NASDAQ:ZYXI) Is Using Debt Safely

Zynex Cures The Pain Of Its Shareholders: Q2 Results

Zynex, Inc. Provides Revenue Guidance for the Third Quarter of 2022

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Zynex: Upside Looks Well Priced In, Efficiency Headwinds Remain

Zynex, Inc. to Report Q2, 2022 Results on Jul 28, 2022

Zynex, Inc. Reiterates Revenue Guidance Full Year 2022

Is Zynex, Inc. (NASDAQ:ZYXI) Trading At A 46% Discount?

Zynex June and Q2 orders hit all-time high, re-affirms Q2 and FY22 guidance

Investor sentiment improved over the past week

Zynex, Inc. (NasdaqGS:ZYXI) announces an Equity Buyback for $10 million worth of its shares.

First quarter 2022 earnings: EPS misses analyst expectations

Insufficient new directors

Zynex, Inc. to Report Q1, 2022 Results on Apr 28, 2022

Is It Time To Consider Buying Zynex, Inc. (NASDAQ:ZYXI)?